证券代码：000626 证券简称：远大控股 公告编号：2025-028 远大产业控股股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、本次股东大会为公司 2024 年度股东大会，采用现场表决与网络投票相结 合的方式召开。现场会议于 2025 年 6 月 30 日 13:30 在浙江省宁波市鄞州区聚贤 街道扬帆路 515 号远大中心 1904 会议室召开，网络投票时间为 2025 年 6 月 30 日，其中：通过深交所交易系统投票的时间为 2025 年 6 月 30 日 9:15——9:25， 9:30——11:30 和 13:00——15:00，通过深交所互联网投票系统投票的时间为 2025 年 6 月 30 日 9:15——15:00。 表决情况：同意 299,648,097 股，占出席本次股东大会有效表决权股份总数 的 99.94425%；反对 125,540 股，占出席本次股东大会有效 ...

法律意见书 致：远大产业控股股份有限公司 浙江导司律师事务所（以下简称"本所"）接受远大产业控股股份有限公司（以 下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员 会《上市公司股东会规则》（以下简称 "《股东会规则》"）、《深圳证券交易 所上市公司股东会网络投票实施细则（2025 年修订）》（以下简称"《深交所网 络投票实施细则》"）等中国现行有效的法律、法规、规范性文件（以下简称"相 关法律、法规"）以及《远大产业控股股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，指派律师出席公司于 2025 年 6 月 30 日召开的 2024 年度股 东大会（以下简称"本次股东大会"），并就本次股东大会相关事项出具法律意见 书。 浙江导司律师事务所 关于远大产业控股股份有限公司 2024 年度股东大会的 本法律意见书仅就本次股东大会的召集和召开程序、出席本次股东大会人员 的资格、召集人资格、本次股东大会表决程序是否符合中国法律、法规及《公司 章程》的规定以及表决结果是否合法有效发表意见，并不对本次股东大 ...

证券代码：000626 证券简称：远大控股 公告编号：2025-027 远大产业控股股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别风险提示： 公司及控股子公司对外担保总额超过公司最近一期经审计净资产 100%；对资产负债率 超过 70%的单位担保金额超过公司最近一期经审计净资产 50%；对合并报表外单位担保金额 超过公司最近一期经审计净资产 30%，敬请投资者关注风险。 一、担保情况概述 远大产业控股股份有限公司（以下简称：公司）与金融机构签署担保文件， 为公司的子公司申请授信提供担保，担保金额不超过 2.1 亿元。本次担保的具体 金额如下： 1、公司为全资子公司远大物产集团有限公司（以下简称：远大物产）向中 国太平洋财产保险股份有限公司宁波分公司（以下简称：太平洋保险）申请授信 提供担保，担保金额不超过 4,000 万元。 2、公司为控股子公司远大石油化学有限公司（以下简称：远大油化）向太 平洋保险申请授信提供担保，担保金额不超过 7,000 万元。 3、公司为远大物产向华夏银行股份有限公司宁波分行（以下简 ...

Meeting Overview - The company is convening its 2024 Annual General Meeting (AGM) on June 30, 2025, as approved by the board on June 9, 2025 [1] - The meeting will be held at the company's office located at 515 Yangfan Road, Ningbo, Zhejiang Province [2] Voting Procedures - The AGM will utilize a combination of on-site and online voting methods, allowing shareholders to vote through the Shenzhen Stock Exchange trading system and an internet voting platform [2][4] - Shareholders must choose either on-site or online voting, with duplicate votes being counted as the first submission [2] Eligibility and Registration - All ordinary shareholders registered by the close of trading on the registration date are eligible to attend and vote at the AGM [2] - Personal shareholders must present valid identification, while corporate shareholders must provide documentation proving their legal representation [4] Agenda Items - The meeting will discuss various proposals, including the appointment of the financial auditing firm for 2025 and matters related to capital reduction and corporate changes [2][5] - Specific proposals will be subject to non-cumulative voting, and shareholders can express their voting intentions on each proposal [5][6] Voting Process Details - Detailed instructions for participating in online voting will be provided, including the need for identity verification through the designated online platform [5] - The voting period for both on-site and online methods will commence at 9:15 AM and conclude at 3:00 PM on June 30, 2025 [5]

证券代码：000626 证券简称：远大控股 公告编号：2025-026 远大产业控股股份有限公司 关于召开 2024 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 远大产业控股股份有限公司（以下简称：公司）董事会于2025年6月10日在 《中国证券报》、《证券时报》和巨潮资讯网（http://www.cninfo.com.cn）披露 了《关于召开2024年度股东大会的通知》，现发布提示性公告，相关情况如下： 一、召开会议的基本情况 1、股东大会届次 本次股东大会为公司 2024 年度股东大会。 2、股东大会的召集人 本次股东大会的召集人为公司董事会，经公司第十一届董事会于 2025 年 6 月 9 日召开的 2025 年度第四次会议审议批准召开本次股东大会。 3、会议召开的合法、合规性 公司董事会认为本次股东大会的召开符合有关法律、行政法规、部门规章、 规范性文件、深交所业务规则和公司《章程》等的规定。 4、会议召开的日期、时间 （1）现场会议召开时间 2025 年 6 月 30 日 13:30。 （2）网络投票时间 2025 年 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

证券代码：000626 证券简称：远大控股 公告编号：2025-025 本次股东大会的召集人为公司董事会，经公司第十一届董事会于 2025 年 6 月 9 日召开的 2025 年度第四次会议审议批准召开本次股东大会。 公司董事会认为本次股东大会的召开符合有关法律、行政法规、部门规章、 规范性文件、深交所业务规则和公司《章程》等的规定。 （1）现场会议召开时间 （2）网络投票时间 其中：通过深交所交易系统投票的时间为 2025 年 6 月 30 日 9:15——9:25， （http://wltp.cninfo.com.cn）投票的时间为 2025 年 6 月 30 日 9:15——15:00。 会议采取现场投票与网络投票相结合的方式召开。公司将通过深圳证券交易 所交易系统和互联网投票系统向公司股东提供网络形式的投票平台，股东可以在 网络投票时间内通过上述系统行使表决权。公司股东只能选择现场投票和网络投 票表决方式中的一种，同一表决权出现重复表决的以第一次投票结果为准。 远大产业控股股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 ...

Group 1 - The company plans to cancel a total of 2,313,600 shares repurchased and reduce its registered capital accordingly, pending approval from the shareholders' meeting [1][2][3] - The repurchase of shares was initially approved in 2022, with a total expenditure of 30,000,778 RMB, and the shares represented 0.45% of the company's total equity [2][3] - After the cancellation, the total share capital will decrease from 508,940,464 shares to 506,626,864 shares, with the structure of shareholding remaining compliant with listing requirements [3][4] Group 2 - The cancellation of repurchased shares is not expected to have a substantial impact on the company's financial status or operational results, and it will not harm the interests of the company or minority investors [3][4] - The company will seek authorization from the shareholders' meeting for management to handle all related procedures for the cancellation and capital reduction [1][3]

Group 1 - The company has approved a capital reduction for its wholly-owned subsidiary GRAND OILS & FOODS (SINGAPORE) PTE.LTD., decreasing its registered capital from 73 million USD to 24.3 million USD, a reduction of 48.7 million USD [1][2] - The capital reduction does not constitute a related party transaction or a significant asset restructuring as defined by regulations [2] - The subsidiary, established in August 2016, reported a sales revenue of 74.51 million USD and a net loss of 1.25 million USD for the fiscal year 2024 [2][3] Group 2 - The purpose of the capital reduction is to optimize the company's asset structure and improve asset management efficiency, which will not significantly impact the company's financial status or operational results [3] - The company holds 100% equity in the subsidiary, which had total assets of 78.73 million USD and net assets of 71.88 million USD as of March 31, 2025 [2][3]

证券代码：000626 证券简称：远大控股 公告编号：2025-024 远大产业控股股份有限公司 关于对全资子公司减资的公告 本次减资不构成关联交易，也不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。本次减资事项尚需提交公司股东大会审议，需要到市场监督 管理部门等部门办理变更及备案手续。 二、远大粮油（新加坡）的基本情况 远大粮油（新加坡）成立于2016年8月11日，注册地点为100 TRAS STREET #09-01 100 AM SINGAPORE，法定代表人为许强。经营范围：自营和代理各类货 物和技术的进出口业务。远大粮油（新加坡）注册资本为7,300万美元，公司持 有其100%股权。 远大粮油（新加坡）2024年度经审计实现销售收入7,451.21万美元，利润总 额-121.24万美元，净利润-125.05万美元；2024年12月31日，资产总额7,870.21 万美元，负债总额685万美元，净资产7,185.21万美元，无或有事项。远大粮油 （新加坡）2025年第一季度未经审计实现销售收入0美元，利润总额2.82万美元， 净利润2.82万美元；2025年3月31日，资产总额7,873. ...